Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights
09. März 2023 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the fiscal year ended December...
Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program
10. November 2022 08:47 ET
|
Blue Water Vaccines Inc.
Closed private placement in August 2022, with net proceeds of approximately $8.7 millionAnnounced plans to evaluate efficacy of BWV-201 for protection against non-invasive pneumococcal pneumonia in...
Blue Water Vaccines to Present at World Vaccine Congress Europe 2022
21. September 2022 08:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom
24. August 2022 14:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights
15. August 2022 16:00 ET
|
Blue Water Vaccines Inc.
Closed private placement in April 2022, with net proceeds of approximately $6.9 millionSigned multiple strategic agreements and collaborations to further vaccine candidate research, development, and...
Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford
31. Mai 2022 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, May 31, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
16. Dezember 2021 07:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety,...